Scarica l'app Stockscreener
0.3787
2.77%
0.0102
Dopo l'orario di chiusura:
.38
0.0013
+0.34%
Precedente Chiudi:
$0.3685
Aprire:
$0.3685
Volume 24 ore:
1.44M
Relative Volume:
0.84
Capitalizzazione di mercato:
$22.68M
Reddito:
-
Utile/perdita netta:
$-41.95M
Rapporto P/E:
-0.4563
EPS:
-0.83
Flusso di cassa netto:
$-38.34M
1 W Prestazione:
-0.37%
1M Prestazione:
+21.65%
6M Prestazione:
-36.36%
1 anno Prestazione:
-86.48%
Intervallo 1D:
$0.3664
$0.3849
Intervallo di 1 settimana:
$0.3616
$0.385
Portata 52W:
$0.221
$3.28
Elevation Oncology Inc Stock (ELEV) Company Profile
Nome
Elevation Oncology Inc
Settore
Industria
Telefono
(716) 371-1125
Indirizzo
101 FEDERAL STREET, BOSTON
Confronta ELEV con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ELEV
Elevation Oncology Inc
|
0.3787 | 22.68M | 0 | -41.95M | -38.34M | -0.83 |
|
VRTX
Vertex Pharmaceuticals Inc
|
457.03 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
547.74 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
329.77 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
545.11 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
244.32 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Elevation Oncology Inc Stock (ELEV) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-03-24 | Downgrade | Stephens | Overweight → Equal-Weight |
| 2025-03-21 | Downgrade | Citizens JMP | Mkt Outperform → Mkt Perform |
| 2025-03-21 | Downgrade | Leerink Partners | Outperform → Market Perform |
| 2025-03-21 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2025-01-03 | Iniziato | William Blair | Outperform |
| 2024-05-31 | Iniziato | Piper Sandler | Overweight |
| 2024-05-14 | Iniziato | Stephens | Overweight |
| 2024-03-01 | Iniziato | JMP Securities | Mkt Outperform |
| 2023-05-30 | Aggiornamento | SVB Securities | Market Perform → Outperform |
| 2021-12-23 | Iniziato | H.C. Wainwright | Buy |
Mostra tutto
Elevation Oncology Inc Borsa (ELEV) Ultime notizie
Analyzing Ratios: Elevation Oncology Inc (ELEV)’s Financial Story Unveiled - DWinneX
Elevation Oncology, Inc. (NASDAQ:ELEV) Sees Large Decline in Short Interest - Defense World
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates FLS, ELEV, MTWO, CRKN on Behalf of Shareholders - GlobeNewswire Inc.
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of - GlobeNewswire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Crown Electrokinetics Corp. (OTCCRKN), Elevation Oncology, Inc. (NasdaqELEV), Sitio Royalties Corp. (NYSESTR), Vigil Neuroscience, Inc. (NasdaqV - TradingView
Research Analysts Set Expectations for ELEV FY2025 Earnings - Defense World
Q2 Earnings Estimate for ELEV Issued By Leerink Partnrs - Defense World
Equities Analysts Issue Forecasts for ELEV Q3 Earnings - Defense World
Wedbush Forecasts Reduced Earnings for Elevation Oncology - Defense World
Elevation Oncology (NASDAQ:ELEV) Cut to “Hold” at TD Cowen - Defense World
HC Wainwright Downgrades Elevation Oncology (NASDAQ:ELEV) to Neutral - Defense World
Elevation Oncology (NASDAQ:ELEV) Stock Rating Lowered by HC Wainwright - Defense World
Elevation Oncology (NASDAQ:ELEV) Downgraded by HC Wainwright to Neutral - Defense World
Elevation Oncology (NASDAQ:ELEV) Receives Market Perform Rating from JMP Securities - Defense World
Elevation Oncology (NASDAQ:ELEV) Lowered to Hold Rating by William Blair - Defense World
Elevation Oncology’s (ELEV) Neutral Rating Reaffirmed at HC Wainwright - Defense World
ELEVATION ONCOLOGY INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Elevation Oncology, Inc.ELEV - Business Wire
Elevation Oncology (ELEV) Receives Analyst Rating Update | ELEV Stock News - GuruFocus
This McDonald's Analyst Turns Bearish; Here Are Top 4 Downgrades For Tuesday - Benzinga
Elevation Oncology (ELEV) Receives Downgrade from HC Wainwright & Co. | ELEV Stock News - GuruFocus
TD Cowen Downgrades Elevation Oncology to Hold From Buy - MarketScreener
HC Wainwright Downgrades Elevation Oncology to Neutral From Buy - marketscreener.com
Elevation Oncology (ELEV) Downgraded by H.C. Wainwright Amid Mer - GuruFocus
Elevation Oncology agrees to be acquired by Concentra - The Pharma Letter
Jane Street Group LLC Acquires 41,215 Shares of Elevation Oncology, Inc. (NASDAQ:ELEV) - Defense World
Millennium Management LLC Boosts Stock Holdings in Elevation Oncology, Inc. (NASDAQ:ELEV) - Defense World
Elevation Oncology agrees to Concentra Biosciences buyout By Investing.com - Investing.com South Africa
Elevation Oncology (ELEV) Downgraded Following Acquisition News - GuruFocus
Elevation Oncology (ELEV) Downgraded by William Blair Following Acquisition Announcement | ELEV Stock News - GuruFocus
Elevation Oncology (ELEV) to be Acquired by Concentra Biosciences | ELEV Stock News - GuruFocus
Concentra to acquire Elevation in bid to eliminate another biotech ‘zombie’ - BioPharma Dive
Elevation Oncology Accepts a Buyout Offer from Concentra Biosciences - marketscreener.com
Concentra Biosciences, LLC entered into a definitive merger agreement to acquire Elevation Oncology, Inc. for $21.4 million. - marketscreener.com
ELEV Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Elevation Oncology, Inc. Is Fair to Shareholders - Business Wire
Elevation Oncology stock soars on Concentra merger agreement By Investing.com - Investing.com South Africa
Elevation Oncology stock soars on Concentra merger agreement - Investing.com Australia
Concentra buys out another struggling Boston biotech - The Business Journals
Elevation Oncology agrees to Concentra Biosciences buyout - Investing.com
Elevation Oncology Says Concentra To Buy Elevation Oncology For $0.36 Per Share Plus CVR - marketscreener.com
Elevation Oncology Merges with Concentra Biosciences - TipRanks
Elevation Oncology Enters into Agreement to Be Acquired by Concentra Biosciences for $0.36 in Cash per Share Plus a Contingent Value Right - PR Newswire
Deutsche Bank AG Has $106,000 Stock Holdings in Elevation Oncology, Inc. (NASDAQ:ELEV) - Defense World
Northern Trust Corp Purchases 59,392 Shares of Elevation Oncology, Inc. (NASDAQ:ELEV) - Defense World
Elevation Oncology, Inc. (NASDAQ:ELEV) Receives Average Rating of “Hold” from Analysts - Defense World
Elevation Oncology Reports Q1 2025 Financial Results - TipRanks
William Blair Remains a Buy on Elevation Oncology (ELEV) - The Globe and Mail
Elevation Oncology Explores Strategic Alternatives - marketscreener.com
Elevation Oncology Advances Novel HER3 ADC Program While Securing Cash Runway Through 2026 - Stock Titan
Elevation Oncology, Inc. SEC 10-Q Report - TradingView
Elevation Oncology Reports First Quarter 2025 Financial Results and Provides Business Updates - PR Newswire
Allogene's Q1 Earnings In Line With Estimates, Sales Nil - Barchart.com
Elevation Oncology Inc Azioni (ELEV) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.45%
0.86%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):